Immuneering Corp — Director's Dealing 2021

Aug 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2021-08-03

Reporting Person: Hall Brett Matthew (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-03	Class A Common Stock	C	5040	—	Acquired	5040	Direct
2021-08-03	Class A Common Stock	P	1353	$15.00	Acquired	6393	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-03	Series A Preferred Stock	$	C	1636	Disposed		Class A Common Stock (1636)	Direct
2021-08-03	Series B Preferred Stock	$	C	3404	Disposed		Class A Common Stock (3404)	Direct

Footnotes

F1: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.